Early results show aducanumab removes amyloid plaques in patients with Alzheimer's disease

Results provide compelling support for the hypothesis that amyloid build-up is a key factor in driving cognitive decline in Alzheimer's disease.

After one year, in patients receiving aducanumab, the levels of amyloid plaques, visualized using positron emission tomography (PET), were substantially reduced. There was also evidence that aducanumab slowed cognitive decline in these patients. Importantly, if confirmed by future trials, these results provide compelling support for the hypothesis that amyloid build-up is a key factor in driving cognitive decline in Alzheimer's disease.

Aducanumab has been developed in collaboration with the leading pharmaceutical company Biogen, and is the product of Neurimmune's proprietary Reverse Translational Medicine (RTM) technology platform. Professor Roger M Nitsch, MD, Co-Founder and President of Neurimmune said: "These results potentially represent a major step forward in the fight against Alzheimer's disease; the magnitudes of the effects as well as their time- and dose-dependency are truly intriguing" He added: "Aducanumab also demonstrates a proof-of-concept for our RTM technology platform. It gives us further evidence that our approach is working and provides promise for many of the other drugs we are developing using this technology."